D. E. Shaw Sells 4.4M Gossamer Bio Shares Amid Distressed Debt Restructuring

summarizeSummary

D. E. Shaw entities sold 4.4 million Gossamer Bio shares in July 2026, reducing their position amid the company's ongoing financial distress and post-restructuring dilution.

check_boxKey Events · Ownership and Investor Activity · GOSS

• 4.4 Million Shares Sold

  D. E. Shaw Valence Portfolios, Cogence, and DESIM sold a combined 4,437,337 shares between July 2 and July 24, 2026, at weighted average prices declining from $0.1707 to $0.1351.

• Persistent Selling Pressure

  Sales occurred on 15 of 17 trading days, with daily volumes ranging from 15,100 to 815,500 shares, indicating a systematic reduction rather than a one-off trade.

• Beneficial Ownership at 7.1%

  Despite the sales, the group's aggregate beneficial ownership remains at 34,609,565 shares (7.1% of outstanding), as the complex entity structure consolidates voting and dispositive power.

• Distressed Backdrop

  The selling follows a May 2026 distressed debt exchange that converted $181M of notes into equity, massively diluting existing holders, and a July 15 shareholder approval of a 4 billion share authorization.

auto_awesomeAnalysis · GOSS · Life Sciences

Between July 2 and July 24, 2026, D. E. Shaw entities sold over 4.4 million shares of Gossamer Bio at prices ranging from $0.12 to $0.20. The selling comes just weeks after a distressed debt exchange massively diluted existing shareholders, and while the stock trades near its lows. Although the group's reported beneficial ownership remains at 7.1% due to the complex entity structure, the sales reduce their economic exposure. For a micro-cap biotech already under severe financial strain, a major institutional holder liquidating shares signals a lack of confidence in the near-term recovery and adds to the overhang on the stock.